Biotech funding roundup: $8M CIRM grant to Siren, $3.5M pre-seed for Claryx, Syntax Bio's $14.4M Series A, €80M Novo Nordisk Foundation programme, and Appili's NIAID contract termination.
Preclinical studies reveal that fructose promotes metastasis in ovarian cancer by reducing cell adhesion, while brigatinib enhances PARP inhibitor efficacy by blocking an early adaptive resistance mechanism. The findings suggest dietary modifications and repurposing a lung cancer drug could improve outcomes for high-grade serous ovarian cancer patients.
A JAMA Oncology study finds breast cancer patients using complementary and alternative medicine face a higher risk of death. A new molecule SU212 shows promise against triple-negative breast cancer, and global breast cancer cases are projected to rise to 3.5 million by 2050.
Transcripta Bio raised $24M backed by Mayo Clinic and Omnimed for AI-driven neurological and neuromuscular therapies. The funds will support IND-enabling studies and clinical preparation for ASD and FSHD programs.
A deep learning pathomics platform called Path-IO accurately predicted outcomes and immunotherapy response in NSCLC patients using routine pathology slides, outperforming the PD-L1 biomarker. The model was validated across multiple cohorts and improved further when combined with radiomics and clinical data. If validated, it could be easily integrated into clinical workflows.
The GE HealthCare-Mayo MI-BET collaboration advances biomarker-guided prostate cancer therapy. The precision oncology market, valued at $122.6B in 2025, is projected to reach $317.2B by 2034, fueled by genomics and targeted treatments.
Alzheimer's blood tests are gaining FDA clearances and strong patient interest, yet surveys show clinicians remain skeptical about their reliability and clinical benefit. A UK survey found fewer than one-third of psychiatrists have used biomarkers, while only 6% of memory services meet access guidelines. An ethical framework urges careful implementation, especially in primary care.
New research shows AI can predict heart disease risk from breast arterial calcification on mammograms, while the BRAIx tool helps assess breast cancer risk. A $16 million U.S. trial, PRISM, will evaluate AI-assisted reading of screening mammograms.
A new U.S. clinical study will test whether provider-mediated communication of colorectal cancer genetic risk increases family genetic testing. The trial plans to enroll around 4,000 patients and relatives.
Merck is expanding its AI efforts through partnerships with Google Cloud and Mayo Clinic. The company said it will deploy AI across R&D and use multimodal clinical datasets to support drug discovery and precision medicine.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07772817 |
Feasibility and Usability of a Chest-Strap Ambulatory ECG Monitor in Active Individuals in Comparison With a Traditional Ambulatory ECG Patch Monitor (MoMe ARC) |
RECRUITING | |
| NCT07769047 |
Semaglutide and Structured Lifestyle Support to Improve Heart and Blood Vessel Health in Postmenopausal Obese Breast Cancer Survivors Taking Aromatase Inhibitors |
NOT_YET_RECRUITING | PHASE4 |
| NCT07757893 |
Precision Medicine for Indolent Systemic Mastocytosis (PRISM) |
NOT_YET_RECRUITING | |
| NCT07756320 |
Precure Targeted Accrual and Rapid Growth in Enrollment Trial Study |
ENROLLING_BY_INVITATION | |
| NCT07755176 |
Patient-reported Outcomes Following Percutaneous Ablation of Desmoid Tumors |
ENROLLING_BY_INVITATION | |
| NCT07752251 |
A Study Of Subscalp Placement Of The LINQII Device |
ENROLLING_BY_INVITATION | NA |
| NCT07745920 |
Managing Depressive Symptoms in ADPKD |
RECRUITING | NA |
| NCT07745894 |
VWCR to Improve Cardiovascular Health and Outcomes Among Cardiac Patients: A Multicenter Randomized Clinical Trial Protocol (Destination Cardiac Rehab Study) |
NOT_YET_RECRUITING | NA |
| NCT07739576 |
Descriptions and Practices of Family Engagement in Emergency Care Setting |
NOT_YET_RECRUITING | |
| NCT07730827 |
Community-Informed Interventions for Equitable Congestive Heart Failure Management in Primary Care |
RECRUITING |
